Netramark signs NetraAI contract with Asklepion

Executive Summary

• Netramark Holdings Inc. has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform for analyzing data from Asklepion's pivotal Phase III pediatric clinical trial.
• The agreement involves using advanced AI technology to analyze patient data from the CIT-003-01 study, which evaluates intravenous L-citrulline for preventing acute lung injury in children undergoing cardiopulmonary bypass surgery.
• The partnership aims to enhance patient stratification and study outcomes by identifying responder personas (subpopulations most likely to benefit from treatment) to inform future study designs.

Key Details

• Contract Parties: Netramark Holdings Inc. (Provider) and Asklepion Pharmaceuticals (Client).
• Technology Deployed: NetraAI platform, utilizing explainable AI and generative modeling.
• Study Context: Asklepion's pivotal Phase III pediatric clinical trial (CIT-003-01).
• Therapeutic Focus: Efficacy of intravenous L-citrulline for preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects.
• Objective: To enhance the ability to demonstrate benefits of L-citrulline in specific patient subgroups and optimize trial design.
• Analytical Focus: Identifying "responder personas" (subpopulations of patients most likely to benefit from treatment) to inform future L-citrulline development.
• Strategic Goal: Leveraging AI to enable precision trial optimization, improve patient stratification, and deliver actionable insights.

Notable Quotes

• "Asklepion's decision to engage Netramark reflects a forward-thinking commitment to innovation in trial design. We are proud to bring our AI-driven capabilities to a program with such clinical importance and look forward to delivering insights that can optimize patient selection and study outcomes." — Josh Spiegel, President of Netramark
• "We are committed to pushing the boundaries of pediatric drug development and Netramark's technology offers a compelling path forward. By integrating NetraAI's explainable AI-based analytics into our late phase study, we hope to uncover meaningful insights that sharpen our understanding of L-citrulline." — Jeff Courtney, CEO at Asklepion Pharmaceuticals
• "This partnership underscores our belief in the power of innovation to accelerate safer, more effective treatments for children." — Dr. Gurdyal Kalsi, Chief Medical Officer at Asklepion Pharmaceuticals